Please Wait
Applying Filters...
menu
    • menu
    Strides Pharma Science-PSE
    News
    Strides Pharma Science Ltd leads losers in 'A' group

    04 Dec 2024

    // BUSINESS STD

    OneSource Pharma Raises Rs 801 Cr via Equity Issuance

    25 Nov 2024

    // BUSINESS STD

    Successful completion of fund raising of USD 95 Mn by Onesource

    25 Nov 2024

    // PRESS RELEASE

    Data Compilation
    #PharmaFlow

    Strides Pharma Science

    Contact Supplier

    Website

    Pharma, Lab & Chemical Expo

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
    Menu

    Strides Pharma Science

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-34447.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-3803.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Manufacturing Sites and R&D Center

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-28236.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2021

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-60913.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Strides Pharma Science Ltd leads losers in 'A' group
    Strides Pharma Science Ltd leads losers in 'A' group

    04 Dec 2024

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/strides-pharma-science-ltd-leads-losers-in-a-group-124120400661_1.html

    BUSINESS STD
    04 Dec 2024
    Share Share
    OneSource Pharma Raises Rs 801 Cr via Equity Issuance
    OneSource Pharma Raises Rs 801 Cr via Equity Issuance

    25 Nov 2024

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/onesource-specialty-pharma-successfully-raises-rs-801-cr-via-equity-issuance-124112500703_1.html

    BUSINESS STD
    25 Nov 2024
    Share Share
    Successful completion of fund raising of USD 95 Mn by Onesource
    Successful completion of fund raising of USD 95 Mn by Onesource

    25 Nov 2024

    // PRESS RELEASE

    https://strides.com/pdf/pressrelease/2024/StridesSEIntimation_25_Nov_2024.pdf

    PRESS RELEASE
    25 Nov 2024
    Share Share
    Strides Pharma jumps on securing NCLT nod for OneSource
    Strides Pharma jumps on securing NCLT nod for OneSource

    21 Nov 2024

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/strides-pharma-jumps-on-securing-nclt-nod-for-onesource-124112100633_1.html

    BUSINESS STD
    21 Nov 2024
    Share Share
    Strides Pharma rises 4% after NCLT nods creation of OneSource
    Strides Pharma rises 4% after NCLT nods creation of OneSource

    21 Nov 2024

    // BUSINESS STD

    https://www.business-standard.com/markets/news/strides-pharma-rises-4-after-nclt-nods-creation-of-onesource-124112100320_1.html

    BUSINESS STD
    21 Nov 2024
    Share Share
    NCLT Approval for creation OneSource India’s 1st Specialty CDMO
    NCLT Approval for creation OneSource India’s 1st Specialty CDMO

    19 Nov 2024

    // PRESS RELEASE

    https://strides.com/pdf/pressrelease/2024/SEIntimationNCLTorder_nov_19_2024.pdf

    PRESS RELEASE
    19 Nov 2024
    Share Share